The Food and Drug Administration today released a final rule regulating certain protein products, such as insulin, as biological products rather than drugs effective March 23. Authorized by the Biologics Price Competition and Innovation Act of 2009, the change will allow new insulin products, and certain other protein products, to apply for marketing approval through the abbreviated pathway for biosimilar or interchangeable products in an effort to increase market competition and lower prices. For more on the change, see the FDA FAQs for health care providers and patients

In other news, FDA today released a table of gene-drug interactions based on FDA labeling and other scientific evidence, which it plans to update periodically to aid prescribers. 
 

Related News Articles

Headline
The House of Representatives last night voted 233-188 along party lines to pass a $1.5 trillion bill (H.R. 2) introduced by Democratic leaders to rebuild…
Headline
Regular surveys and reviews by The Joint Commission will resume this month, the commission announced last week. TJC, which had suspended surveys during the…
Headline
The Department of Health and Human Services Tuesday reminded health care providers that HIPAA privacy rules bar them from giving media and film crews access to…
Headline
Members of the Partnership to Amend 42 CFR Part 2, including the AHA, today urged the Department of Health and Human Services to issue a rule as soon as…
Headline
The Department of Health and Human Services’ Office for Civil Rights yesterday said it generally will not impose penalties for HIPAA rule violations on health…
Headline
The Department of Health and Human Services' Office for Civil Rights April 3 warned HIPAA-covered entities of an individual posing as an OCR investigator…